– Formal notice confirms intent to grant patent for pharmaceutical tetracycline compositions for dermatological use –WOODCLIFF LAKE, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical tetracycline (including minocycline) compositions for dermatological use (U.S. Patent Application No.: 16/514,459).“The notice of allowance from the USPTO further protects our dermatology portfolio,” said John Koconis, Chief Executive Officer of Timber. “Our stable topical composition of minocycline is the result of many years of research and development and has the potential to reduce side effects associated with oral systemic delivery in the treatment of dermatologic conditions.”This notice confirms the allowance of additional claims relative to the Company’s BPX-01 and BPX-04 assets including the Company’s method for treating an active dermatological inflammation or infection, including acne or rosacea, by applying the topical compositions to an inflamed or infected area of skin at least once daily for a period of at least one month.Timber previously announced its intention to evaluate its proprietary topical programs, BPX-01 and BPX-04, in the treatment of inflammatory lesions of acne vulgaris and papulopustular rosacea for a strategic partnership, co-development or other non-dilutive value creation strategy. Timber believes the expansion of claims for this patent will further protect these assets.About Timber Pharmaceuticals, Inc.Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company’s investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit https://www.timberpharma.com/.Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.For more information, contact:Timber Pharmaceuticals, Inc. 
John Koconis 
Chief Executive Officer
[email protected]Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
[email protected]Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
[email protected]

Bay Street News